Correspondence
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma
R. Sinha,
R. Sinha
Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH U.K.
Search for more papers by this author K. Lecamwasam,
K. Lecamwasam
Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH U.K.
Search for more papers by this author K. Purshouse,
K. Purshouse
Department of Oncology, University of Oxford, Oxford, U.K.
Search for more papers by this author J. Reed,
J. Reed
Department of Oncology, University of Oxford, Oxford, U.K.
Search for more papers by this author M.R. Middleton,
M.R. Middleton
Department of Oncology, University of Oxford, Oxford, U.K.
Search for more papers by this author L. Fearfield,
L. Fearfield
Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH U.K.
Search for more papers by this author
R. Sinha,
R. Sinha
Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH U.K.
Search for more papers by this author K. Lecamwasam,
K. Lecamwasam
Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH U.K.
Search for more papers by this author K. Purshouse,
K. Purshouse
Department of Oncology, University of Oxford, Oxford, U.K.
Search for more papers by this author J. Reed,
J. Reed
Department of Oncology, University of Oxford, Oxford, U.K.
Search for more papers by this author M.R. Middleton,
M.R. Middleton
Department of Oncology, University of Oxford, Oxford, U.K.
Search for more papers by this author L. Fearfield,
L. Fearfield
Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH U.K.
Search for more papers by this author
First published: 20 December 2013
No abstract is available for this article.
References
- 1Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–16.
- 2Sinha R, Edmonds K, Newton-Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987–94.
- 3Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149–53.
- 4Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69: e1–13.
